Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.820
+0.130 (4.83%)
At close: Sep 26, 2025, 4:00 PM EDT
2.810
-0.010 (-0.35%)
After-hours: Sep 26, 2025, 7:34 PM EDT
MRVI Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for MRVI stock ranges from a low of $2.00 to a high of $10. The average analyst price target of $5.25 forecasts a 86.17% increase in the stock price over the next year.
Price Target: $5.25 (+86.17%)
Analyst Consensus: Hold
* Price targets were last updated on Aug 12, 2025.
Analyst Ratings
The average analyst rating for MRVI stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +77.30% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +254.61% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -29.08% | May 13, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +77.30% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | -11.35% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
195.57M
from 259.19M
Decreased by -24.54%
Revenue Next Year
209.71M
from 195.57M
Increased by 7.23%
EPS This Year
-0.31
from -1.05
EPS Next Year
-0.20
from -0.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 213.7M | 234.2M | |||
| Avg | 195.6M | 209.7M | |||
| Low | 181.7M | 188.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -17.6% | 19.7% | |||
| Avg | -24.5% | 7.2% | |||
| Low | -29.9% | -3.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.24 | -0.07 | |
| Avg | -0.31 | -0.20 | |
| Low | -0.38 | -0.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.